Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer

摘要

Background: At least half of the patients diagnosed with non-muscle-invasive bladder cancer (NMIBC) experience recurrence and approximately 15% will develop progression to muscle invasive or metastatic disease. Biomarkers for disease surveillance are urgently needed.